Acne Vulgaris - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 200
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1FF4E1E589EN
Leaflet:

Download PDF Leaflet

Acne Vulgaris - Pipeline Review, H2 2016
Acne Vulgaris - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 8, 22, 9, 2, 17 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Acne Vulgaris.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
Pipeline Products for Acne Vulgaris - Overview
Pipeline Products for Acne Vulgaris - Comparative Analysis
Acne Vulgaris - Therapeutics under Development by Companies
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
Acne Vulgaris - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acne Vulgaris - Products under Development by Companies
Acne Vulgaris - Products under Investigation by Universities/Institutes
Acne Vulgaris - Companies Involved in Therapeutics Development
3SBIO INC.
Allergan Plc
Almirall, S.A.
Antibiotx ApS
Biomar Microbial Technologies
BiopharmX, Inc.
Braintree Laboratories, Inc.
Brickell Biotech, Inc.
Cell Medica Limited
Cellceutix Corporation
Celtaxsys, Inc.
Common Pharma Inc
Cutanea Life Sciences Inc
DermaXon, LLC
Dermira Inc.
Diffusion Pharmaceuticals Inc.
ELORAC, Inc.
Ensol Biosciences Inc.
Foamix Pharmaceuticals Ltd.
Galderma S.A.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Limited
LEO Pharma A/S
Novabiotics Limited
Novan, Inc.
Paratek Pharmaceuticals, Inc.
Pfizer Inc.
Phosphagenics Limited
Photocure ASA
Promius Pharma, LLC
Provectus Biopharmaceuticals, Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sol-Gel Technologies Ltd.
Sun Pharma Advanced Research Company Ltd.
Telesso Technologies Limited
Thesan Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Vectura Group Plc
Vyome Biosciences Private Limited
XBiotech Inc
Xenon Pharmaceuticals Inc.
Acne Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(adapalene + clindamycin hydrochloride) - Drug Profile
(benzoyl peroxide + tretinoin) - Drug Profile
(clindamycin phosphate + tretinoin) - Drug Profile
A-3APO - Drug Profile
acebilustat - Drug Profile
Aczone Combo - Drug Profile
Aczone X - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
AQ-401 - Drug Profile
ATx-202 - Drug Profile
B-244 - Drug Profile
BBI-3000 - Drug Profile
benzoyl peroxide - Drug Profile
BLI-1100 - Drug Profile
botulinum toxinA - Drug Profile
brilacidin tetrahydrochloride - Drug Profile
CB-0301 - Drug Profile
CB-0601 - Drug Profile
CLS-007 - Drug Profile
dapsone - Drug Profile
DFD-10 - Drug Profile
DLX-2323 - Drug Profile
DLX-2681 - Drug Profile
DMT-210 - Drug Profile
DRM-01 - Drug Profile
DX-0385 - Drug Profile
E-10215 - Drug Profile
finasteride - Drug Profile
FMX-101 - Drug Profile
GSK-1940029 - Drug Profile
HB-1345 - Drug Profile
Hesed-4000 - Drug Profile
IB-07A037 - Drug Profile
IDP-120 - Drug Profile
IDP-121 - Drug Profile
IDP-123 - Drug Profile
IDP-126 - Drug Profile
IDP-129 - Drug Profile
IDP-130 - Drug Profile
ivermectin - Drug Profile
LEO-43204 - Drug Profile
LTA-001 - Drug Profile
methyl aminolevulinate hydrochloride - Drug Profile
minocycline - Drug Profile
minocycline - Drug Profile
minocycline hydrochloride - Drug Profile
MTC-896 - Drug Profile
omiganan pentahydrochloride - Drug Profile
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
PF-06423264 - Drug Profile
PH-10 - Drug Profile
RA-18C3 - Drug Profile
RES-440 - Drug Profile
sarecycline hydrochloride - Drug Profile
SB-204 - Drug Profile
SKP-026 - Drug Profile
Small Molecule for Acne and Skin Inflammation - Drug Profile
Small Molecules for Acne Vulgaris - Drug Profile
Synthetic Peptide for Acne Vulgaris - Drug Profile
Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile
tazarotene - Drug Profile
tretinoin - Drug Profile
tretinoin - Drug Profile
trifarotene - Drug Profile
TSN-2898 - Drug Profile
Vaccine for Acne Vulgaris - Drug Profile
VB-1953 - Drug Profile
XEN-801 - Drug Profile
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 195

LIST OF TABLES

Number of Products under Development for Acne Vulgaris, H2 2016
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Acne Vulgaris - Pipeline by 3SBio Inc., H2 2016
Acne Vulgaris - Pipeline by Allergan Plc, H2 2016
Acne Vulgaris - Pipeline by Almirall, S.A., H2 2016
Acne Vulgaris - Pipeline by Antibiotx ApS, H2 2016
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2016
Acne Vulgaris - Pipeline by BiopharmX, Inc., H2 2016
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2016
Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H2 2016
Acne Vulgaris - Pipeline by Cell Medica Limited, H2 2016
Acne Vulgaris - Pipeline by Cellceutix Corporation, H2 2016
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2016
Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2016
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2016
Acne Vulgaris - Pipeline by DermaXon, LLC, H2 2016
Acne Vulgaris - Pipeline by Dermira Inc., H2 2016
Acne Vulgaris - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2016
Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H2 2016
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Acne Vulgaris - Pipeline by Galderma S.A., H2 2016
Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H2 2016
Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H2 2016
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2016
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2016
Acne Vulgaris - Pipeline by Novabiotics Limited, H2 2016
Acne Vulgaris - Pipeline by Novan, Inc., H2 2016
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016
Acne Vulgaris - Pipeline by Pfizer Inc., H2 2016
Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2016
Acne Vulgaris - Pipeline by Photocure ASA, H2 2016
Acne Vulgaris - Pipeline by Promius Pharma, LLC, H2 2016
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016
Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd., H2 2016
Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Acne Vulgaris - Pipeline by Telesso Technologies Limited, H2 2016
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Acne Vulgaris - Pipeline by Vectura Group Plc, H2 2016
Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H2 2016
Acne Vulgaris - Pipeline by XBiotech Inc, H2 2016
Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acne Vulgaris - Dormant Projects, H2 2016
Acne Vulgaris - Dormant Projects (Contd..1), H2 2016
Acne Vulgaris - Dormant Projects (Contd..2), H2 2016
Acne Vulgaris - Dormant Projects (Contd..3), H2 2016
Acne Vulgaris - Dormant Projects (Contd..4), H2 2016
Acne Vulgaris - Dormant Projects (Contd..5), H2 2016
Acne Vulgaris - Dormant Projects (Contd..6), H2 2016
Acne Vulgaris - Discontinued Products, H2 2016 186

LIST OF FIGURES

Number of Products under Development for Acne Vulgaris, H2 2016
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Acne Vulgaris - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: